Investors

Latest Financial Results

Q1 2024

Quarterly Results

Ended Jan 31, 2024

Stock Information

Symbol

ANIX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.  Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.  The company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.  These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.  Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.

Logo Itus

Latest News & Events

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

Read More...

Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

Read More...

Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines

Read More...